FDA issues safety warning for newer hepatitis C drugs following patient deaths

FDA issues safety warning for newer hepatitis C drugs following patient deaths

Source: 
Biopharma Dive
snippet: 

More than 60 cases filed in the FAERS database detail how patients experienced worsening liver health after taking AbbVie's Mavyret, Merck & Co.'s Zepatier or Gilead's Vosevi.